New drug duo shows promise against tough cancers

NCT ID NCT05516914

Completed Disease control Sponsor: Nanjing Leads Biolabs Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, LBL-007 and tislelizumab, in 98 adults with advanced solid tumors. The goal was to see if the combo is safe, tolerable, and effective at shrinking tumors. Researchers also looked at how the drugs move through the body and whether they trigger an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LBL-007 combined with tislelizumab (and sometimes chemotherapy drugs like cisplatin, gemcitabine, or docetaxel)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced solid tumors that are hard to treat.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 98 participants, so results may not apply broadly. Side effects from combining these drugs are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT TUMORS

Contacts and locations

Locations

Anhui Cancer Hospital

Hefei, Anhui, 230031, China
Fujian Cancer Hospital

Fuzhou, Fujian, 350001, China
Guangxi Medical University Cancer Hospital

Nanning, Guangxi, 530000, China
Hubei Cancer Hospital

Wuhan, Hubei, 430000, China
Huizhou Municipal Central Hospital

Huizhou, Guangdong, 516000, China
Hunan Cancer Hospital

Changsha, Hunan, 410000, China
Jiangxi Cancer Hospital

Nanchang, Jiangxi, 330029, China
Sun Yat-Sen Memorial Hospital，Sun Yat-Sen University

Guangzhou, Guangdong, 510120, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, 530021, China
The First People's Hospital of Yu Lin

Yulin, Guangxi, 537000, China
The Second Affiliated Hospital of Hainan Medical University

Haikou, Hainan, 570000, China
Union Hospital Tongji Medical College Huazhong University of Science And Technology

Wuhan, Hubei, 430022, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China
Zhejiang Cancer Hospital

Hangzhou, Hangzhou, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.